For the analyses of the effect of metformin on BCR and the all-cause mortality of prostate cancer, all of the studies were retrospective cohorts in design, and the total number of prostate cancer cases included was 2953 and 9241, respectively. This evidence concerns the gene BCR and prostate carcinoma.